Payment overview · 2025
General Payments
$541.85
24 reported records · 15 companies
Healthcare provider profile · identity verified
John Eric Port, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MIDLOTHIAN, VA · NPI 1912936154
Verified facts
What the public records show
CMS Open Payments records show John Eric Port, M.D. received $541.85 in general payments during 2025 across 24 reported records.
Dexcom, Inc. accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $76.91 | 14.2% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $62.94 | 11.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.95 | 9.4% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $49.42 | 9.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.75 | 7.3% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $38.76 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.29 | 7.1% | 2 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $32.43 | 6.0% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $27.07 | 5.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.59 | 4.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.11 | 4.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.38 | 4.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.48 | 3.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.89 | 3.5% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.88 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $541.85 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.91 | 4 | 2025 |
Source payment records
|
|||||
| Magnets OEM Normalized: magnets oem |
Device | Philips North America LLC | $62.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.95 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.95 | 3 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $49.42 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $38.76 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $38.29 | 2 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $24.59 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.38 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.48 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $15.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 812 | 229 |
| Amlodipine Besylate | Amlodipine Besylate | 669 | 179 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 513 | 145 |
| Losartan Potassium | Losartan Potassium | 435 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 115 |
| Lisinopril | Lisinopril | 391 | 110 |
| Omeprazole | Omeprazole | 315 | 86 |
| Pantoprazole Sodium | Pantoprazole Sodium | 310 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 283 | 80 |
| Trazodone Hcl | Trazodone Hcl | 267 | 75 |
| Gabapentin | Gabapentin | 263 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 71 |
| Metformin Hcl Er | Metformin Hcl | 255 | 76 |
| Simvastatin | Simvastatin | 254 | 73 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 238 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 221 | 63 |
| Clonazepam | Clonazepam | 194 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 191 | 48 |
| Alprazolam | Alprazolam | 178 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 173 | 40 |
| Tramadol Hcl | Tramadol Hcl | 173 | 48 |
| Synthroid | Levothyroxine Sodium | 172 | 39 |
| Montelukast Sodium | Montelukast Sodium | 170 | 50 |
| Bupropion Xl | Bupropion Hcl | 167 | 44 |
| Ozempic | Semaglutide | 164 | 30 |
| Allopurinol | Allopurinol | 149 | 38 |
| Sertraline Hcl | Sertraline Hcl | 146 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 37 |
| Glipizide Er | Glipizide | 135 | 41 |
| Eliquis | Apixaban | 134 | 32 |
| Jardiance | Empagliflozin | 131 | 30 |
| Metformin Hcl | Metformin Hcl | 120 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 120 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 33 |
| Ezetimibe | Ezetimibe | 116 | 35 |
| Furosemide | Furosemide | 109 | 45 |
| Finasteride | Finasteride | 106 | 27 |
| Prednisone | Prednisone | 105 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 104 | 40 |
| Famotidine | Famotidine | 104 | 31 |
| Meloxicam | Meloxicam | 104 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 19 |
| Chlorthalidone | Chlorthalidone | 100 | 31 |
| Spironolactone | Spironolactone | 99 | 30 |
| Farxiga | Dapagliflozin Propanediol | 97 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 35 |
| Valsartan | Valsartan | 95 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 43 |
| Atenolol | Atenolol | 90 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 89 | 11 |
| Lorazepam | Lorazepam | 88 | 19 |
| Donepezil Hcl | Donepezil Hcl | 83 | 20 |
| Carvedilol | Carvedilol | 82 | 23 |
| Irbesartan | Irbesartan | 81 | 20 |
| Potassium Chloride | Potassium Chloride | 81 | 20 |
| Trulicity | Dulaglutide | 79 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 23 |
| Myrbetriq | Mirabegron | 76 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 20 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Xarelto | Rivaroxaban | 74 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 30 |
| Ondansetron Odt | Ondansetron | 67 | 33 |
| Azelastine Hcl | Azelastine Hcl | 66 | 25 |
| Buspirone Hcl | Buspirone Hcl | 65 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 65 | 18 |
| Valacyclovir | Valacyclovir Hcl | 64 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 17 |
| Mirtazapine | Mirtazapine | 61 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 16 |
| Clonidine Hcl | Clonidine Hcl | 59 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 54 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 13 |
| Risperidone | Risperidone | 46 | 11 |
| Telmisartan | Telmisartan | 46 | 12 |
| Glimepiride | Glimepiride | 44 | 13 |
| Memantine Hcl | Memantine Hcl | 44 | 11 |
| Baclofen | Baclofen | 43 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 28 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 40 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 14 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 16 |
| Cephalexin | Cephalexin | 33 | 25 |
| Diazepam | Diazepam | 33 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | 13 |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 28 |
| Methylprednisolone | Methylprednisolone | 28 | 21 |
| Mupirocin | Mupirocin | 28 | 17 |
| Azithromycin | Azithromycin | 27 | 24 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Oxycontin | Oxycodone Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Nystatin | Nystatin | 23 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 16 |
| Naproxen | Naproxen | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 21 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Calcitriol | Calcitriol | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | 14 |
| Meclizine Hcl | Meclizine Hcl | 19 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Keppra | Levetiracetam | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $541.85 · 24 records | Dexcom, Inc. | CeQur Simplicity, Cologuard Collection Kit, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), FREESTYLE LIBRE 3, Heplisav-B, INCEPTIV, INJECTAFER, INSPIRE, KISUNLA, Leqembi, Magnets OEM, NURTEC ODT, OPSUMIT, The Cologuard Plus Collection Kit, UPTRAVI, WAINUA, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error